Outcomes of hematopoietic stem cell transplantation using melphalan-based conditioning in children with acquired aplastic anemia
Open Access
- 30 June 2025
- journal article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 55-61
Abstract
Despite the high effectiveness of hematopoietic stem cell transplantation (HSCT) in children with acquired aplastic anemia (AAA), the procedure can still result in such major issues as graft failure and rejection. Risk factors for graft rejection and poor function as well as the persistence of mixed chimerism include allosensitization, insufficient number of transplanted cells and relatively preserved native myelopoiesis. Long-term engraftment can be achieved by modifying conditioning and immunosuppressive therapy. One such promising approach is the inclusion of melphalan in a conditioning regimen. In our study, we retrospectively analyzed outcomes of HSCT with melphalan-based conditioning carried out in 21 children with AAA (for 18 patients, it was their first HSCT, while 3 had a repeat HSCT): out of these, 11 patients received transplants from matched unrelated donors, 9 received transplants from matched related donors and 1 - from a haploidentical donor. Nine children received calcineurin inhibitor-based graft-versus-host disease prophylaxis while 12 children received Janus kinase inhibitors. A good graft function was achieved in all the children, without any severe complications. As per the latest findings, 95% of the patients achieved full total donor cell chimerism, 85.7% of the patients had full donor chimerism in the CD3+ cell lineage, while 14.3% had mixed CD3+ cell chimerism with 9-13% of own cells. The inclusion of melphalan in a conditioning regimen in patients with AAA before HSCT in combination with new less toxic graft-versus-host disease prophylaxis regimens may be an effective strategy to overcome the risk of graft rejection and ensure a low toxicity profile and low incidence of complications. The study was approved by the Independent Ethics Committee and the Scientific Council of the N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation.Keywords
This publication has 9 references indexed in Scilit:
- Aplastic anemia: history and recent developments in diagnosis and treatmentInternational Journal of Hematology, 2024
- The EBMT Handbook2024
- Anti-Thymocyte Globulin (ATG)-Free Nonmyeloablative Haploidentical PBSCT Plus Post-Transplantation Cyclophosphamide Is a Safe and Efficient Treatment Approach for Pediatric Acquired Aplastic AnemiaInternational Journal of Molecular Sciences, 2022
- Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamideBone Marrow Transplantation, 2020
- Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell TransplantationFrontiers in Immunology, 2016
- Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantationBlood, 2011
- Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working partyHaematologica, 2010
- Leukocyte Reduction and Ultraviolet B Irradiation of Platelets to Prevent Alloimmunization and Refractoriness to Platelet TransfusionsNew England Journal of Medicine, 1997
- Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemiaBlood, 1994